TOP TEN perturbations for 39130_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39130_at
Selected probe(set): 212156_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39130_at (212156_at) across 6674 perturbations tested by GENEVESTIGATOR:
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)
Relative Expression (log2-ratio):1.9510002Number of Samples:2 / 5
| Experimental | colorectal cancer study 43 (metastase; brain) |
| Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
| Control | colorectal cancer study 43 (metastase; lung) |
| Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma. |
colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)
Relative Expression (log2-ratio):1.8982353Number of Samples:2 / 25
| Experimental | colorectal cancer study 43 (metastase; brain) |
| Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma. | |
| Control | colorectal cancer study 43 (metastase; liver) |
| Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):1.672636Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):1.3721418Number of Samples:4 / 4
| Experimental | B-CLL study 11 (DMSO) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
| Control | vehicle (DMSO) treated normal B-cell sample |
| MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
kidney transplantation study 15 (4 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):1.3376293Number of Samples:2 / 5
| Experimental | kidney transplantation study 15 (4 week) |
| CD14+ monocyte samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal monocyte (CD14+) sample |
| CD14+ monocyte samples derived from healthy control subjects. |
Olea pollen extract study 1 (allergic; pollen season) / Olea pollen extract study 1 (non-allergic; pollen season)
Relative Expression (log2-ratio):-1.2894983Number of Samples:3 / 2
| Experimental | Olea pollen extract study 1 (allergic; pollen season) |
| Peripheral blood mononuclear cells (PBMC) obtained during pollen season (April-June) from pollen-allergic patients were cultured for 24 hours in the presence of whole olive pollen extract (25µg/ml). The patients fulfilled the following criteria: seasonal rhinitis and/or asthma, a positive skin prick test for O. europaea pollen extract, and no previous immunotherapy. Each sample represents equimolar amounts of RNA from two subjects, samples were pooled prior labeling and hybridization. (Warning: Experiment with gender bias). | |
| Control | Olea pollen extract study 1 (non-allergic; pollen season) |
| Peripheral blood mononuclear cells (PBMC) obtained during pollen season (April-June) from patients with no history of respiratory allergies were cultured for 24 hours in the presence of whole olive pollen extract (25µg/ml). All subjects underwent skin prick test for olive pollen allergy with whole O. europaea extract and a battery of common allergens. Each sample represents equimolar amounts of RNA from two subjects, samples were pooled prior labeling and hybridization. (Warning: Experiment with gender bias). |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.2711763Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.2278633Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):-1.2228699Number of Samples:4 / 6
| Experimental | F. tularensis study 1 (novicida) |
| Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
| Control | uninfected peripheral blood monocyte sample |
| Peripheral blood monocytes uninfected. |
Alzheimer's disease study 7 / normal pyramidal neuron (hippocampus)
Relative Expression (log2-ratio):-1.1984444Number of Samples:10 / 12
| Experimental | Alzheimer's disease study 7 |
| Pyramidal neurons collected from the CA1 region of the hippocampus of clinically and neuropathologically classified late-onset Alzheimer´s disease afflicted individuals. Subjects in this group had a Braak stage of V or VI with a CERAD score of moderate or frequent. | |
| Control | normal pyramidal neuron (hippocampus) |
| Pyramidal neurons collected from the CA1 region of the hippocampus of clinically classified as neurologically normal individuals. Subjects in this group had a Braak stage ranging from I to II with a infrequent Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque density. |